{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T05:17:32Z","timestamp":1788585452819,"version":"build-2803163510"},"reference-count":37,"publisher":"Japan Atherosclerosis Society","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2026,9,1]]},"DOI":"10.5551\/jat.66152","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:09:48Z","timestamp":1779314988000},"page":"1180-1193","source":"Crossref","is-referenced-by-count":0,"title":["Cross-Sectional Association of Lipoprotein(a) Levels With Vascular Complications and Related Parameters in a Japanese Type 2 Diabetes Cohort"],"prefix":"10.5551","volume":"33","author":[{"given":"Tsutomu","family":"Hirano","sequence":"first","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Uetani","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Nakata","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuko","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ema","family":"Aoki","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Hirashima","sequence":"additional","affiliation":[{"name":"Diabetes Center, Ebina General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuki","family":"Ito","sequence":"additional","affiliation":[{"name":"Clinical Diagnostics Development Department, Denka Co., Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Utermann G, Weber W. Protein composition of Lp(a) lipoprotein from human plasma. FEBS Lett, 1983; 154: 357-361","DOI":"10.1016\/0014-5793(83)80182-3"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Bor\u00e9n J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokg\u00f6zoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J, 2017; 38: 2459-2472","DOI":"10.1093\/eurheartj\/ehx144"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, Michos ED, Miedema MD, Mu\u00f1oz D, Smith SC Jr, Virani SS, Williams KA Sr, Yeboah J, Ziaeian B. 2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019; 140: e596-e646","DOI":"10.1161\/CIR.0000000000000678"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Nordestgaard BG, Chapman MJ, Ray K, Bor\u00e9n J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokg\u00f6zoglu L, Tybj\u00e6rg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J, 2010; 31: 2844-2853","DOI":"10.1093\/eurheartj\/ehq386"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kronenberg F, Mora S, Stroes ESG, Ference BA, Arsenault BJ, Berglund L, Dweck MR, Koschinsky M, Lambert G, Mach F, McNeal CJ, Moriarty PM, Natarajan P, Nordestgaard BG, Parhofer KG, Virani SS, von Eckardstein A, Watts GF, Stock JK, Ray KK, Tokg\u00f6zo\u011flu LS, Catapano AL. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. Eur Heart J, 2022; 43(: 3925-3946","DOI":"10.1093\/eurheartj\/ehac361"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, Lloyd-Jones DM, Marcovina SM, Yeang C, Koschinsky ML; American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol, 2022 ; 42: e48-e60","DOI":"10.1161\/ATV.0000000000000147"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) O\u2019Donoghue ML, Rosenson RS, Gencer B, L\u00f3pez JAG, Lepor NE, Baum SJ, Stout E, Gaudet D, Knusel B, Kuder JF, Ran X, Murphy SA, Wang H, Wu Y, Kassahun H, Sabatine MS; OCEAN(a)-DOSE Trial Investigators. Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. N Engl J Med, 2022; 387: 1855-1864","DOI":"10.1056\/NEJMoa2211023"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med, 2009; 361: 2518-2528","DOI":"10.1056\/NEJMoa0902604"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yoshida H, Kroes M, Sakai Y, Takahashi Y, Yamanaka Y, Crawford B, Ako J. Lipoprotein(a) in Japanese Patients With Cardiovascular Disease: A Systematic Review. JACC Asia, 2025; 5: 1525-1539","DOI":"10.1016\/j.jacasi.2025.08.017"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Corral P, Matta MG, Schreier L. Are Lipoprotein(a) levels decreased in insulin resistance and type 2 diabetes? Curr Opin Lipidol, 2025; 36: 179-184","DOI":"10.1097\/MOL.0000000000000996"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Kostner KM, Kostner GM. Lp(a) and the Risk for Cardiovascular Disease: Focus on the Lp(a) Paradox in Diabetes Mellitus. Int J Mol Sci, 2022; 23: 3584","DOI":"10.3390\/ijms23073584"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, Ridker PM. Lipoprotein(a) and risk of type 2 diabetes. Clin Chem, 2010; 56: 1252-1260","DOI":"10.1373\/clinchem.2010.146779"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Ding L, Song A, Dai M, Xu M, Sun W, Xu B, Sun J, Wang T, Xu Y, Lu J, Wang W, Bi Y, Ning G. Serum lipoprotein (a) concentrations are inversely associated with T2D, prediabetes, and insulin resistance in a middle-aged and elderly Chinese population. J Lipid Res, 2015; 56: 920-926","DOI":"10.1194\/jlr.P049015"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Sone H, Tanaka S, Iimuro S, Tanaka S, Oida K, Yamasaki Y, Oikawa S, Ishibashi S, Katayama S, Yamashita H, Ito H, Yoshimura Y, Ohashi Y, Akanuma Y, Yamada N; Japan Diabetes Complications Study Group. Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes: a nationwide multicentre randomised controlled trial (the Japan Diabetes Complications Study). Diabetologia, 2010; 53: 419-428","DOI":"10.1007\/s00125-009-1622-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Konishi H, Miyauchi K, Shitara J, Endo H, Wada H, Doi S, Naito R, Tsuboi S, Ogita M, Dohi T, Kasai T, Okazaki S, Isoda K, Suwa S, Daida H. Impact of Lipoprotein(a) on Long-term Outcomes in Patients With Diabetes Mellitus Who Underwent Percutaneous Coronary Intervention. Am J Cardiol, 2016 5; 118: 1781-1785","DOI":"10.1016\/j.amjcard.2016.08.067"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Hirano T, Satoh N, Kodera R, Hirashima T, Suzuki N, Aoki E, Oshima T, Hosoya M, Fujita M, Hayashi T, Ito Y. Dyslipidemia in diabetic kidney disease classified by proteinuria and renal dysfunction: A cross-sectional study from a regional diabetes cohort. J Diabetes Investig, 2022; 13: 657-667","DOI":"10.1111\/jdi.13697"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Miida T, Hirayama S, Fukushima Y, Hori A, Ito S, Hinata M, Wakita M, Tabata H, Tamura Y, Watada H, Kawamori R, Vesper HW, Cobbaert CM. Harmonization of Lipoprotein(a) Immunoassays Using A Serum Panel Value Assigned with The IFCC-Endorsed Mass Spectrometry-Based Reference Measurement Procedure as A First Step Towards Apolipoprotein Standardization. J Atheroscler Thromb, 2025; 32: 580-595","DOI":"10.5551\/jat.65238"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C, Fowkes FG, Hiatt WR, J\u00f6nsson B, Lacroix P, Marin B, McDermott MM, Norgren L, Pande RL, Preux PM, Stoffers HE, Treat-Jacobson D; American Heart Association Council on Peripheral Vascular Disease; Council on Epidemiology and Prevention; Council on Clinical Cardiology; Council on Cardiovascular Nursing; Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation, 2012; 126: 2890-2909","DOI":"10.1161\/CIR.0b013e318276fbcb"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Katakami N, Kaneto H, Shimomura I. Carotid ultrasonography: A potent tool for better clinical practice in diagnosis of atherosclerosis in diabetic patients. J Diabetes Investig, 2014; 5: 3-13","DOI":"10.1111\/jdi.12106"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y, Igarashi M. Lipoprotein(a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors. The Jichi Medical School Cohort Study. Am J Epidemiol, 1995; 141: 815-821","DOI":"10.1093\/oxfordjournals.aje.a117516"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Abe A, Noma A. Studies on apolipoprotein(a) phenotypes. Part 1. Phenotype frequencies in a healthy Japanese population. Atherosclerosis, 1992; 96: 1-8","DOI":"10.1016\/0021-9150(92)90032-C"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Arafa A, Kato Y, Kokubo Y, Khairan P, Matsumoto C, M Nakao Y, Kataoka Y, Harada-Shiba M. Lipoprotein(a) Levels and the Risk of Coronary Heart Disease and Stroke: The Suita Study. J Atheroscler Thromb, 2025; 32: 1139-1149","DOI":"10.5551\/jat.65437"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Fujii E, Ako J, Takahashi Y, Toda M, Iekushi K, Yamashita S. Serum Lipoprotein(a) Levels and Their Association with Atherosclerotic Cardiovascular Disease in Japan. J Atheroscler Thromb, 2025; 32: 421-438","DOI":"10.5551\/jat.64953"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Hopewell JC, Haynes R, Baigent C. The role of lipoprotein (a) in chronic kidney disease. J Lipid Res, 2018; 59: 577-585","DOI":"10.1194\/jlr.R083626"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Thiery J, Ivandic B, Bahlmann G, Walli AK, Seidel D. Hyperlipoprotein(a)aemia in nephrotic syndrome. Eur J Clin Invest, 1996; 26: 316-321","DOI":"10.1046\/j.1365-2362.1996.132283.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Hiraishi C, Matsui S, Kojima T, Sato R, Ando K, Fujimoto K, Yoshida H. Association of Renal Function and Statin Therapy with Lipoprotein(a) in Patients with Type 2 Diabetes. J Atheroscler Thromb, 2024; 31: 81-89","DOI":"10.5551\/jat.64261"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Gholami Chahkand MS, Esmaeilpour Moallem F, Qezelgachi A, Seifouri K, Pesaran Afsharian A, Sheikhzadeh F, Poursalehi A, Fani Sadrabadi FS, Saghab Torbati M, Ramezanzade M, Alishiri G, Ansari A, Zare Dehabadi E, Karimi Matloub S, Sheikh Z, Deravi N, Mehrtabar S, Chichagi F, Faal Hamedanchi N, Arzaghi M, Asadi M, Alsadat Dadkhah P, Ansari A. Lipoprotein (a) as a predictor of diabetic retinopathy in patients with type 2 diabetes: A systematic review. Diab Vasc Dis Res, 2023; 20: 14791641231197114","DOI":"10.1177\/14791641231197114"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Lampsas, S.; Lambadiari, V.; Agapitou, C.; Lampsa, A.; Oikonomou, E.; Siasos, G.; Chatziralli, I. Lipoprotein (a) in the Development and Progression of Diabetic Retinopathy: A Systematic Review and Meta-Analysis. Medicina, 2025; 61: 1137","DOI":"10.3390\/medicina61071137"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Marth E, Cazzolato G, Bittolo Bon G, Avogaro P, Kostner GM. Serum concentrations of Lp(a) and other lipoprotein parameters in heavy alcohol consumers. Ann Nutr Metab, 1982; 26: 56-62","DOI":"10.1159\/000176544"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Mehta A, Lee TB, Alebna P, Grandhi GR, Dixon DL, Salloum FN, Sanyal AJ, Siddiqui MS. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia. J Clin Lipidol, 2023; 17: 828-833","DOI":"10.1016\/j.jacl.2023.09.003"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Li C, Li M, Wang Z. There is a linear negative correlation between lipoprotein(a) and non-alcoholic fatty liver disease. Sci Rep, 2025; 15: 8538","DOI":"10.1038\/s41598-025-93518-z"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Chemello K, Chan DC, Lambert G, Watts GF. Recent advances in demystifying the metabolism of lipoprotein(a). Atherosclerosis, 2022; 349: 82-91","DOI":"10.1016\/j.atherosclerosis.2022.04.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Langsted A, Nordestgaard BG, Kamstrup PR. Elevated Lipoprotein(a) and Risk of Ischemic Stroke. J Am Coll Cardiol, 2019; 74: 54-66","DOI":"10.1016\/j.jacc.2019.03.524"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Gurdasani D, Sjouke B, Tsimikas S, Hovingh GK, Luben RN, Wainwright NW, Pomilla C, Wareham NJ, Khaw KT, Boekholdt SM, Sandhu MS. Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol, 2012; 32: 3058-3056","DOI":"10.1161\/ATVBAHA.112.255521"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Tsimikas S, Gordts PLSM, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J, 2020; 41: 2275-228","DOI":"10.1093\/eurheartj\/ehz310"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Ikezaki H, Lim E, Cupples LA, Liu CT, Asztalos BF, Schaefer EJ. Small Dense Low-Density Lipoprotein Cholesterol Is the Most Atherogenic Lipoprotein Parameter in the Prospective Framingham Offspring Study. J Am Heart Assoc, 2021; 10: e019140","DOI":"10.1161\/JAHA.120.019140"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Koba S, Satoh N, Ito Y, Yokota Y, Tsunoda F, Sakai K, Nakamura Y, Shoji M, Hirano T, Shinke T. Impact of Direct Measurement of Small Dense Low-Density Lipoprotein Cholesterol for Long-Term Secondary Prevention in Patients with Stable Coronary Artery Disease. Clin Chem, 2024; 70: 957-966","DOI":"10.1093\/clinchem\/hvae061"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_66152\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:52:45Z","timestamp":1788583965000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/33\/9\/33_66152\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":37,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.66152","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]},"article-number":"66152"}}